Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ACADEMIA
ACADEMIA
- Japan Esophageal Society to Recommend 5-FU + Cisplatin as 1st-Line Therapy for Esophageal Cancer in New Guidelines
July 7, 2016
- MHLW Working Group Drafting Guidelines for Development of Cell Therapies for Cerebral Infarction
July 4, 2016
- Accelerate Investigator-Initiated Trials to Promote Academia-Led Drug Discovery: New NCGM Research Center Chief
July 1, 2016
- 865,238 People Diagnosed with Cancer in 2012: NCC
June 30, 2016
- MHLW Study Group Aims to Formulate Guidelines for Treatment of Skeletal Dysplasias in FY2017
June 29, 2016
- Nexium, Takecab Added to Standard Treatments for 1st Eradication of H. Pylori: JSHR Guidelines
June 28, 2016
- PD-1’s “Actual Physiology Remains Unclear”: Discoverer of PD-1
June 21, 2016
- No Increased Mortality Risks Seen in Japanese AD Patients on Antipsychotics: Study
June 17, 2016
- Victoza 1st GLP-1 Agent to Thwart Cardiovascular Events; Will It Catch on?
June 15, 2016
- Academic Societies Drafting Guidelines for Clinically Evaluating Efficacy of Drugs for AMR Infectious Diseases
June 15, 2016
- As Spate of Melanoma Drugs Debut, Physicians Still Exploring Best Drug Choices, Combos
June 14, 2016
- Gilead’s 2 Hep C Treatments Highly Effective in Actual Clinical Practice: Multicenter Studies Results
May 24, 2016
- Diabetes Society Calls for Careful Administration of SGLT-2 Inhibitors to Geriatric Syndrome Patients, Aged 75 or Over
May 19, 2016
- MHLW Study Group Drafting Guidelines for Assessing Cost-Effectiveness of Vaccines Proposed for Inclusion in Public Vaccination Programs
May 16, 2016
- Use Patient Registries for Orphan, Intractable Diseases First: MHLW Study Group Chief
May 9, 2016
- At Least 20% of Patients Taking Xeljanz against Guidelines: Interim Analysis of PMS
April 26, 2016
- AMED Study Team Drafting First Guidelines for Diagnosis and Treatment of Post-Stroke Epilepsy
April 21, 2016
- 17 Japanese Medical Societies Jointly Recommend HPV Vaccines
April 20, 2016
- Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
- It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…